Medindia

X

Amgen’s Prolia Approved to Treat Bone Loss in Prostate and Breast Cancer Patients

by Kathy Jones on  September 20, 2011 at 7:03 PM Drug News   - G J E 4
The market for Amgen Inc's Prolia has been expanded for two new uses after the US Food and Drug Administration approved the osteoporosis drug to be used for treating bone loss among patients with breast cancer and non-metastatic prostate cancer.
 Amgen’s Prolia Approved to Treat Bone Loss in Prostate and Breast Cancer Patients
Amgen’s Prolia Approved to Treat Bone Loss in Prostate and Breast Cancer Patients
Advertisement

The drug was initially approved by the FDA last year to treat osteoporosis among post-menopausal women. In July 2010 the FDA gave a priority review for Prolia with regard to its ability to reduce skeletal-related events in cancer patients with bone metastases.

Advertisement
The latest approval by the health regulator allows it to be used in treating bone loss among women who have undergone adjuvant aromatase inhibitor therapy for breast cancer and men who have opted for hormone therapy to recover from prostate cancer.

The new approval is based on the results of two phase III studies that showed improved bone mineral density (BMD) with this molecule in patients with prostate cancer and breast cancer.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All